. n p 6 n p 5 n p 2 n p 2 Conclusion. The population of fluoroquinolone-resistant S. pneumoniae in the United States has increased but remains genetically diverse. However, 35% of LNSP were related to widespread pneumococcal clones, increasing the potential for the rapid spread of quinolone resistance in this species.
Global dissemination of a limited number of antimicrobial-resistant clones has been a major factor in the emergence of antimicrobial resistance in Streptococcus pneumoniae during the past decade [1, 2] . The reason that these clones have been dominant in the antimicrobial-resistant pneumococcal population is unknown, but emergence of resistance to new antimicrobials in these clones will likely accelerate the spread of resistance [1, 2] .
Fluoroquinolone resistance among pneumococci is primarily caused by mutations in the quinolone resistance-determining regions (QRDRs) of parC and gyrA floxacin-resistant pneumococci in the United States and Canada is !1% [6, [16] [17] [18] . The highest rates of levofloxacin resistance have been reported in Hong Kong (13.3%-14.3%) and are associated with the dissemination of a strain related to the Spain 23F -1 clone [12, 15] . Reports of genetic heterogeneity among fluoroquinolone-resistant isolates from other regions suggest that fluoroquinolone resistance in S. pneumoniae has emerged primarily through de novo mutational events [15, [19] [20] [21] [22] . Fluoroquinolone resistance has been reported in isolates from throughout the world that are closely related to the Spain 23F -1 and other widespread pneumococcal clones [15, 19, 21] .
The role of interspecies recombination in the emergence of fluoroquinolone resistance among pneumococci appears to be minor [23, 24] . Evidence of the transfer of resistance genes from viridans group streptococci to S. pneumoniae was found in 11% of 46 ciprofloxacin-resistant isolates from Spain but in only 1 of 71 ciprofloxacin-resistant isolates from Canada [23, 24] . Efflux pumps have been demonstrated in some pneumococcal isolates, but this has primarily been in isolates with low-level quinolone resistance [3, 8] .
The purpose of this study was to determine the prevalence of fluoroquinolone resistance among S. pneumoniae in the United States during [2001] [2002] and to characterize the QRDR mutations in this population. A second objective was to examine the genetic relatedness of pneumococcal isolates from 1994-2002 with parC and/or gyrA mutations and to determine their prevalence within widespread clones of antimicrobialresistant S. pneumoniae.
METHODS
As part of a longitudinal surveillance program, 1902 S. pneumoniae isolates were collected from 45 medical centers throughout the United States during the winter of [2001] [2002] and Miami Beach (12) , Tampa (7), and Jacksonville (51), Florida. The major specimen types were blood (25%), lower respiratory tract (50%), ear (6%), sinus (5%), upper respiratory tract (5%), eye (4%), and CSF (1%).
Susceptibility testing was performed using the NCCLS broth microdilution method [25] , and resistance was defined according to NCCLS interpretive standards [26] . Resistance to ciprofloxacin was defined as an MIC of у4 mg/mL [11] . The fluoroquinolones tested were levofloxacin, ciprofloxacin, gatifloxacin, and moxifloxacin. Susceptibility test results for penicillin, erythromycin, tetracycline, trimethoprim-sulfamethoxazole, and chloramphenicol were used to determine whether there was multidrug resistance (defined as nonsusceptibility to penicillin and у2 non-blactam, nonquinolone antimicrobials).
One hundred sixty-two isolates were selected from the 2001-2002 surveillance study for mutation analysis of the QRDRs of genes encoding topoisomerase IV (parC and parE) and DNA gyrase (gyrA and gyrB). All of the 52 isolates with ciprofloxacin MICs of у4 mg/mL, 86 (18%) of 472 isolates with ciprofloxacin MICs of 2 mg/mL, and 24 (2%) of the 1099 isolates with ciprofloxacin MICs of 1 mg/mL were analyzed for QRDR mutations. DNA amplification and sequencing to detect QRDR mutations was performed as described elsewhere [6] .
The genetic relatedness of isolates with parC and/or gyrA mutations from the 2001-2002 collection and 3 US surveillance studies conducted during [1994] [1995] [1997] [1998] , and 1999-2000 was determined by PFGE. In vitro susceptibility and QRDR mutation data for the 1994-2000 isolates have been reported previously [6] . Thirty-two of the 45 centers participating in the 2001-2002 study also contributed isolates during the 1994-2000 surveillance period.
PFGE was performed on isolates with parC and/or gyrA mutations using a simplified protocol for S. pneumoniae [27] . SmaI (250 U/mL) was used for DNA digestion, followed by PFGE with a CHEF-DR II apparatus (Bio-Rad) at 200 V (14ЊC for 20 h; initial forward time, 1 s; final forward time, 20 s). After ethidium bromide staining, the gels were photographed with the Bio-Rad Gel Doc 1000 system (Bio-Rad). Analysis of the PFGE patterns was performed with Bionumerics software (Applied Maths). The unweighted pair group method with arithmetic averages was used to construct a dendrogram with the Dice coefficient, a 1.0% optimization setting, and a 1.0% position tolerance. Isolates differing by р3 bands were considered to be closely related (genetic relatedness of у84% on the dendrogram) and assigned to the same PFGE type [28] .
PFGE was also performed on 26 -26) and compared with the surveillance isolate PFGE profiles [1] .
The capsular serotype of each isolate with parC and/or gyrA mutations was determined by the quellung reaction with typespecific antisera (Statens Serum Institut). The relationship between quinolone resistance and PFGE type, QRDR mutation, serotype, and resistance to other agents was examined. The significance of group proportion differences was assessed with the x 2 test or Fisher's exact test. The most common mutation was a single Ile-460rVal mutation in parE detected in 78 isolates. All except 1 of the 78 isolates with a single parE mutation were susceptible to levofloxacin, and 85% were susceptible to ciprofloxacin. Of the 30 isolates with parC mutations (with or without parE mutations), 60% were ciprofloxacin susceptible, and 97% were levofloxacin susceptible. In contrast, every isolate with a gyrA mutation (20 isolates, 90% of which also had a parC mutation) was resistant to ciprofloxacin and levofloxacin (MIC, у8 mg/mL). All 5 isolates with gyrB and parC mutations were resistant to cipro- floxacin, and 40% were resistant to levofloxacin. All 6 isolates with a gyrB mutation (with or without a parE mutation) were susceptible to levofloxacin, and only 2 of the isolates were resistant to ciprofloxacin. The fluoroquinolone susceptibility and QRDR analysis results for isolates from the 4 study periods are summarized in table 2. The overall prevalences of isolates with ciprofloxacin and levofloxacin MICs of у4 mg/mL among the 6549 surveillance isolates were 1.7% ( ) and 0.7% ( ), ren p 114 n p 47 spectively. parC And/or gyrA mutations (selection criteria for PFGE) were found among 111 of the 326 isolates analyzed for QRDR mutations: 29 (26%) of the isolates had parC and gyrA mutations, 76 (68%) had parC mutations only, and 6 (5%) had gyrA mutations only.
RESULTS

Susceptibility test results
The 111 isolates with parC and/or gyrA mutations were assigned to 48 different PFGE types: 56 (50%) were in 7 major PFGE types with у5 members, 28 (25%) were in 14 minor PFGE types with 1-3 members, and 27 (24%) were unique (tables 3 and 4). Forty-four isolates (40%) belonged to 8 The 111 isolates with parC and/or gyrA mutations belonged to 117 different serotypes (figure 1). The most common serotypes were 23F (22 isolates), 19F (15 isolates), 9V (10 isolates), 11A (9 isolates), 6A (7 isolates), 31 (7 isolates), 6B (6 isolates), and 4 (5 isolates). Isolates in 15 of the 21 PFGE types with multiple isolates shared the same serotype (table 3 ). An association between particular serotypes or PFGE types and specific QRDR mutations was not apparent.
The predominant parC mutations were Ser-79rPhe or Tyr (59 isolates, 54% of which were LNSP), Lys-137rAsn (43 isolates, 19% of which were LNSP), and Asp-83rTyr, Asn, or Val (16 isolates, 38% of which were LNSP) (table 4). Every isolate with a gyrA mutation was not susceptible to levofloxacin. The predominant gyrA mutation detected was Ser-81rPhe, Tyr, or Ala. The only gyrB mutation detected in LNSP was Asp435rAsn or Glu. The predominant parE mutation detected among the 111 isolates was Ile-460 (30% of LNSP).
Forty-three (39%) of the 111 isolates with parC and/or gyrA mutations were LNSP and assigned to 29 different PFGE types ( . All except 1 of the 37 levofloxacinresistant isolates had a gyrA or gyrB mutation (usually also parC). Five of the 6 levofloxacin-intermediate isolates only had a parC mutation (with or without a parE mutation); 1 had a parC mutation and a gyrA mutation. No more than 2 isolates in a PFGE type contained identical QRDR mutations among all 4 genes.
Of the 6 levofloxacin-intermediate isolates included in table 5, 83% were susceptible to gatifloxacin, and all were susceptible to moxifloxacin. All of the levofloxacin-resistant isolates were gatifloxacin nonsusceptible, 78% were moxifloxacin nonsusceptible, 46% were penicillin nonsusceptible, and 38% were multidrug resistant. The overall prevalences of penicillin nonsusceptibility and multidrug resistance for the 6549 isolates from the 4 study periods were 30% and 18%, respectively. All of the LNSP related to the Spain 23F -1, Spain 6B -2, and Taiwan 19F -14 clones were multidrug resistant.
Many isolates had multiple QRDR mutations, making the significance of some mutations difficult to discern. The fluoroquinolone MICs of the subset of the isolates analyzed by PFGE that had relatively isolated QRDR mutations are presented in table 6 . Among isolates with a single parC mutation (with or without an Ile-460 parE mutation), 75% of isolates with Ser-79 mutations were ciprofloxacin resistant, but only 17% were levofloxacin nonsusceptible. Similarly, all 8 isolates with a single Asp-83 parC mutation were ciprofloxacin resistant, but they were susceptible to the other 3 quinolones tested. In contrast, only 17% of isolates with a single Lys-137 parC mutation were resistant to ciprofloxacin. Among the 23 isolates with an Ile-460 parE mutation (no gyrA; no Ser-79 or Asp-83 parC mutations), only 13% had elevated MICs of ciprofloxacin (i.e., 4 mg/mL).
DISCUSSION
This study demonstrates a statistically significant increase in the prevalence of LNSP in the United States, from 0. [16] . The Centers for Disease Control and Prevention (CDC) reported a rate of levofloxacin resistance (MIC, у8 mg/mL) of 0.2% among 3475 invasive isolates collected in the 1998 period of the Active Bacterial Core Surveillance program [17] . In 1997-1998, our surveillance indicated a higher rate of levofloxacin resistance (0.4%), which may be explained by our inclusion of respiratory specimens [6] . During 1994-2002, significantly more isolates from the lower respiratory tract (1.1%) were LNSP, compared with isolates from blood (0.4%) ( ). A higher prevalence of levofloxacin resis-P p .006 tance among lower respiratory tract isolates, compared with Only a subset (88.3%) of the 111 isolates were analyzed for parE mutations, as follows: PFGE type A, 89.5%; B, C, D, F, H, K, L, M, N, P, Q, R, S, T, and U, 100%; E, 80%; G, 60%; I, J, 66.7%; O, 50%; and unique PFGE types, 81.5%. blood isolates, was also noted among 1998-2002 TRUST isolates [16] . Higher rates of levofloxacin resistance among penicillinnonsusceptible isolates have been reported elsewhere [16, 17] . The overall prevalence of LNSP among penicillin-susceptible isolates from 1994-2002 was 0.6%, whereas the prevalence of LNSP among penicillin-nonsusceptible isolates was 1.1% ( ). The current study also demonstrated a significantly P p .042 higher prevalence of LNSP among multidrug-resistant isolates (1.5% vs. 0.6%;
). P p .002 As expected, all isolates with gyrA mutations (Ser-81 and Glu-85) were not susceptible to ciprofloxacin, levofloxacin, and gatifloxacin. Although some of these isolates with gyrA mutations remained "susceptible" to moxifloxacin according to NCCLS breakpoints, the efficacy of using this agent in these isolates needs to be proven with clinical studies [10] . The Glu-85 gyrA mutations were identified in 2 of the 8 moxifloxacinsusceptible, levofloxacin-resistant isolates. Although the Glu-85 gyrA mutation was only found among 2001-2002 isolates in our longitudinal surveillance, it was previously identified in levofloxacin-resistant isolates from the United States and Canada [8, 15, 20, 22] .
In the present study, the only parC mutations that were consistently associated with ciprofloxacin resistance were Ser-79 and Asp-83. None of the parE mutations appeared to be significant. The only gyrB mutation associated with a levofloxacin-resistant phenotype was Asp-435.
The serotype distribution of the isolates with QRDR mutations was more diverse than is typically found among penicillin-resistant pneumococci. The serotypes of 91% of penicillin-resistant isolates from a 1998 CDC study (6A, 6B, 9V, 14, 19A, 19F, and 23F) [17] accounted for only 60% of the 43 LNSP isolates and 61% of the 111 isolates with parC and/or gyrA mutations in this study. The serotypes included in the heptavalent conjugate vaccine (4, 6B, 9V, 14, 18C, 19F, and 23F) accounted for 53% of the 43 LNSP in this study.
The genetic diversity of the LNSP was greater than that demonstrated among penicillin-resistant isolates (MIC, у2 mg/mL) from the first 3 study periods. More than 75% of the penicillinresistant isolates were assigned to 12 major PFGE types containing у8 isolates [29] . In contrast, only 47% of the 43 LNSP clustered in a PFGE type with another LNSP isolate, and only 3 PFGE types included у3 isolates.
The 2 PFGE types with the largest number of LNSP were closely related to widespread Pneumococcal Molecular Epidemiology Network clones (Spain 23F -1 and Spain 6B -2) with 14% and 12% of the LNSP isolates, respectively. The variations in geographic source, QRDR mutations, and serotypes among isolates related to the Spain [15] . Despite the detection of multiple fluoroquinolone-resistant isolates closely related to widespread clones in many countries, only surveillance isolates from Hong Kong provide clear evidence of an increase in fluoroquinolone resistance associated with clonal spread [12, 15, 30] . All 10 fluoroquinolone-resistant isolates from Hong Kong reported in the 1999-2000 PROTEKT study shared the same multilocus sequence testing (MLST) profile as the Spain 23F -1 clone; 9 of the isolates were serotype 14 with identical Ser-81rPhe gyrA and Ser-79rPhe parC mutations [15, 30] . Among 180 pneumococci collected in Hong Kong in 2000, 13% were LNSP, and all shared the same MLST profile as the Spain [12] .
Although the population of quinolone-nonsusceptible pneumococci in the United States has increased, it continues to be small and genetically diverse. However, 40% of isolates with QRDR mutations and 35% of LNSP were closely related to widespread pneumococcal clones that contributed to the spread of antibiotic resistance in this species during the past decade. The potential for a rapid increase in fluoroquinolone resistance associated with clonal dissemination appears to be growing.
